The 15q13.3 microdeletion is a recurrent CNV, presumably mediated by NAHR between segmental duplications in chromosome 15. The 15q13.3 deletion and duplication are associated with a wide range of clinical manifestations, such as intellectual deficits, seizures, autism, language and developmental delay, neuropsychiatric impairments, and behavioral problems illustrating incomplete penetrance and expressivity. This study comprises an evaluation of 106 symptomatic patients carrying the heterozygous deletion, as well as of 21 patients carrying the duplication, who have been described in previous studies. The analysis shows considerable heterogeneity for the manifestation of different key symptoms and familiar occurrence. Furthermore, 8 new patients are introduced. Convoluted familiar connections give new insights into the complexity of symptomatic manifestation. In previous studies, different opinions have been expressed as to the nature and precise location of the deletion breakpoints. Here, we show that not CHRNA7 and CHRFAM7A, but rather FAM7A or GOLGA8, serve as breakpoint regions concerning our patients. The deletion is described as heterogeneous in size. However, we assume that not only different breakpoints but also the imprecision of aCGH analysis on chromosome 15 due to segmental duplications accounts for the variability in size.

Keywords:
Copy number variations, Segmental duplications, Microdeletion 15q13.3
1.
Antonacci F, Dennis MY, Huddleston J, Sudmant PH, Steinberg KM, et al: Palindromic GOLGA8 core duplicons promote chromosome 15q13.3 microdeletion and evolutionary instability. Nat Genet 46:1293-1302 (2014).
2.
Chaignat E, Yahya-Graison EA, Henrichsen CN, Chrast J, Schütz F, et al: Copy number variation modifies expression time courses. Genome Res 21:106-113 (2011).
3.
Dibbens LM, Mullen S, Helbig I, Mefford HC, Bayly MA, et al: Familial and sporadic 15q13.3 microdeletions in idiopathic generalized epilepsy: precedent for disorders with complex inheritance. Hum Mol Genet 18:3626-3631 (2009).
4.
Freedman R, Leonard S, Gault JM, Hopkins J, Cloninger CR, et al: Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 105:20-22 (2001).
5.
Henrichsen CN, Chaignat E, Reymond A: Copy number variants, diseases and gene expression. Hum Mol Genet 18:R1-R8 (2009).
6.
Le Pichon JB, Yu S, Kibiryeva N, Graf WD, Bittel DC: Genome-wide gene expression in a patient with 15q13.3 homozygous microdeletion syndrome. Eur J Hum Genet 21:1093-1099 (2013).
7.
Lowther C, Costain G, Stavropoulos DJ, Melvin R, Silversides CK, et al: Delineating the 15q13.3 microdeletion phenotype: a case series and comprehensive review of the literature. Genet Med 17:149-157 (2015).
8.
Mikhail FM, Lose EJ, Robin NH, Descartes MD, Rutledge KD, et al: Clinically relevant single gene or intragenic deletion encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorder. Am J Med Genet A 155A:2386-2396 (2011).
9.
Poot M, van der Smagt JJ, Brilstra EH, Bourgeron T: Disentangling the myriad genomics of complex disorders, specifically focusing on autism, epilepsy, and schizophrenia. Cytogenet Genome Res 135:228-240 (2011).
10.
Sharp AJ, Mefford HC, Li K, Baker C, Skinner C, et al: A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat Genet 40:322-328 (2008).
11.
Shinawi M, Schaaf CP, Bhatt SS, Xia Z, Patel A, et al: A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes. Nat Genet 41:1269-1271 (2009).
12.
Sinkus ML, Wamboldt MZ, Barton A, Fingerlin TE, Laudenslager ML, Leonard S: The α7 nicotinic acetylcholin receptor and the acute stress response: maternal genotype determines offspring phenotype. Physiol Behav 104:321-326 (2011).
13.
Szafranski P, Schaaf CP, Person RE, Gibson IB, Xia Z, et al: Structures and molecular mechanisms for common 15q13.3 microduplications involving CHRNA7: benign or pathological? Hum Mutat 31:840-850 (2010).
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.